Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + mitomycin C + fluorouracil
- Development stage
- Unknown
- Lead developer
- University Medical Center Hamburg-Eppendorf
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This chemotherapy regimen is a combination of cisplatin, mitomycin C, and fluorouracil (5-FU) used in the treatment of locally advanced oropharyngeal cancer. It is specifically associated with the TopROC clinical trial (Transoral Surgery vs Radiochemotherapy for Oropharyngeal Cancer) conducted by the Universitätsklinikum Hamburg-Eppendorf. Cisplatin and mitomycin C function as DNA-damaging agents that induce cross-links and alkylation, thereby inhibiting DNA replication and transcription. Fluorouracil is an antimetabolite that inhibits thymidylate synthase, an enzyme essential for DNA synthesis. In the TopROC trial, this regimen is evaluated as part of primary radiochemotherapy or as adjuvant therapy following transoral head and neck surgery.
- Other names
- chemotherapy-Universitätsklinikum Hamburg-Eppendorf-oropharyngeal cancerTopROC chemotherapy regimen
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cisplatin + mitomycin C + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + mitomycin C + fluorouracil.